Karyopharm Therapeutics Inc. (KPTI): Nasdaq/NYSE listing notice — Karyopharm receives Nasdaq deficiency notice for bid price below $1.00 per share

Karyopharm Therapeutics Inc.

Received deficiency letter on Dec 6, 2023 for failing to meet Nasdaq's $1.00 minimum bid price rule for 30 consecutive business days.
Has until June 3, 2024 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
If non-compliant by June 3, may seek additional 180-day period by transferring to Nasdaq Capital Market and potentially effecting a reverse stock split.
Company's common stock remains listed on Nasdaq Global Select Market during the 180-day compliance period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Karyopharm Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

December 6, 2023, Karyopharm Therapeutics Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Glo

View on SEC.gov

Browse all listing & compliance notices →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-293373

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.